Gold (DrugBank: Gold)
38 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 3 |
| 5 | 進行性核上性麻痺 | 1 |
| 6 | パーキンソン病 | 14 |
| 13 | 多発性硬化症／視神経脊髄炎 | 5 |
| 17 | 多系統萎縮症 | 2 |
| 34 | 神経線維腫症 | 2 |
| 46 | 悪性関節リウマチ | 6 |
| 49 | 全身性エリテマトーデス | 1 |
| 50 | 皮膚筋炎／多発性筋炎 | 2 |
| 53 | シェーグレン症候群 | 1 |
| 65 | 原発性免疫不全症候群 | 1 |
| 68 | 黄色靱帯骨化症 | 1 |
| 76 | 下垂体性ゴナドトロピン分泌亢進症 | 2 |
| 84 | サルコイドーシス | 2 |
| 86 | 肺動脈性肺高血圧症 | 5 |
| 91 | バッド・キアリ症候群 | 1 |
| 93 | 原発性胆汁性胆管炎［原発性胆汁性肝硬変 (~2017.3)］ | 2 |
| 95 | 自己免疫性肝炎 | 1 |
| 96 | クローン病 | 4 |
| 97 | 潰瘍性大腸炎 | 2 |
| 98 | 好酸球性消化管疾患 | 1 |
| 113 | 筋ジストロフィー | 1 |
| 158 | 結節性硬化症 | 1 |
| 162 | 類天疱瘡（後天性表皮水疱症を含む。） | 1 |
| 171 | ウィルソン病 | 2 |
| 218 | アルポート症候群 | 1 |
| 222 | 一次性ネフローゼ症候群 | 3 |
| 224 | 紫斑病性腎炎 | 1 |
| 227 | オスラー病 | 1 |
| 230 | 肺胞低換気症候群 | 1 |
| 271 | 強直性脊椎炎 | 1 |
| 291 | ヒルシュスプルング病（全結腸型又は小腸型） | 1 |
| 294 | 先天性横隔膜ヘルニア | 1 |
| 296 | 胆道閉鎖症 | 5 |
| 298 | 遺伝性膵炎 | 1 |
| 299 | 嚢胞性線維症 | 1 |
| 310 | 先天異常症候群 | 1 |
| 318 | シトリン欠損症 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03843710 (ClinicalTrials.gov) | April 30, 2021 | 14/2/2019 | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis (REPAIR-ALS) | A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: Gold Nanocrystals | Clene Nanomedicine | University of Texas Southwestern Medical Center | Not yet recruiting | 35 Years | 75 Years | All | 24 | Phase 2 | United States |
| 2 | ChiCTR1900024520 | 2019-07-22 | 2019-07-13 | Split-hand index calculated by F-wave test apply to the diagnosis of amyotrophic lateral sclerosis | Split-hand index calculated by F-wave test apply to the diagnosis of amyotrophic lateral sclerosis | Amyotrophic lateral sclerosis | Gold Standard:Clinical outcome meet the Awaji-Shima Criteria 2008;Index test:Split-hand index calculated by F-wave test; | Peking Union Medical College Hospita | NULL | Recruiting | 18 | 80 | Both | Target condition:300;Difficult condition:50 | N/A | China |
| 3 | NCT03690791 (ClinicalTrials.gov) | January 9, 2019 | 13/9/2018 | Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease | A Randomised, Double-blind, Single-centre Study on the Safety, Tolerability and Efficacy of Cannabis Based Medicine Extract (MediCabilis CBD Oil) in Slowing the Disease Progression in Amyotrophic Lateral Sclerosis or Motor Neurone Disease Patients | Amyotrophic Lateral Sclerosis;Motor Neuron Disease | Drug: MediCabilis CBD Oil;Drug: Placebo Oil | Gold Coast Hospital and Health Service | BOD Australia | Recruiting | 25 Years | 80 Years | All | 30 | Phase 3 | Australia |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000030512 | 2019-05-13 | 2020-03-05 | Clinical study of [18F]-APN-1607([18F]-PM-PBB3) PET on tau tangles in the brain of progressive supranuclear palsy | Clinical study of [18F]-APN-1607([18F]-PM-PBB3) PET on tau tangles in the brain of progressive supranuclear palsy | progressive supranuclear palsy | Gold Standard:clinical diagnosis of progressive supranuclear palsy the movement disorder society criteria in 2017.(Mov Disord. 2017 Jun;32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.).;Index test:Standard uptake value ratio of [18F]-APN-1607([18F]-PM-PBB3); | Huashan Hospital, Fudan University | NULL | Recruiting | 45 | 80 | Both | Target condition:26;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000038937 | 2020-11-01 | 2020-10-10 | Clinical study of early diagnosis of Parkinson's disease based on substantia nigra-striatal axis multimodal imaging | Clinical study of early diagnosis of Parkinson's disease based on substantia nigra-striatal axis multimodal imaging | Parkinson's disease | Gold Standard:Clinical diagnosis by experienced movement disorder specialists after 2 years of follow-up.;Index test:Including traditional imaging feature algorithms (SUVR value, total cortical volume, bilateral cortical surface area, cortical thickness, etc.), high-dimensional imaging omics feature algorithms (energy entropy, gray-level co-occurrence matrix, and mutual information, etc.), and brain connection group Learning feature algorithm.; | Huashan Hospital, Fudan University | NULL | Recruiting | 45 | 80 | Both | Target condition:105;Difficult condition:0 | China | |
| 2 | ChiCTR2000036137 | 2020-10-01 | 2020-08-21 | Clinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's disease | Clinical study of 18F-FDG combined with 18F-AV-133 PET/CT imaging in the diagnosis and differentiation of primary Parkinson's disease | Parkinson’s disease | Gold Standard:UK Parkinson's disease Society Brain Bank Clinical Diagnosis Criteria;Index test:18F-FDG combined with 18F-AV-133 PET/CT imaging; | Renji Hospital (South Court), School of Medicine, Shanghai Jiao Tong University | NULL | Pending | Both | Target condition:50;Difficult condition:0 | China | |||
| 3 | ChiCTR2000036006 | 2020-10-01 | 2020-08-21 | The applications of multi- MRI in early diagnosis of Parkinson's Disease based on deep learning | The applications of multi- MRI in early diagnosis of Parkinson's Disease based on deep learning | Parkinson's disease | Gold Standard:MDS clinical diagnostic criteria for Parkinson’s disease;Index test:multimodal MRI features in locus coeruleus and substantia nigra; | Zhongshan Hospital, Fudan University | NULL | Pending | 18 | 85 | Both | Target condition:400;Difficult condition:0 | China | |
| 4 | ChiCTR2000037856 | 2020-10-01 | 2020-09-02 | Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA) | Detection of A-synuclein Aggregate as Biomarker in Diagnosing Parkinson's Disease at Early Stage by Using Protein Misfolding Cyclic Amplification (PMCA) | Parkinson's Disease | Gold Standard:DAT-PET and 18F-FDG PET ;Index test:a-synuclein protein misfolding cyclic amplification; | Huashan Hospital Affiliated to Fudan University | NULL | Recruiting | 50 | 75 | Both | Target condition:150;Difficult condition:76 | China | |
| 5 | ChiCTR2000037239 | 2020-10-01 | 2020-08-27 | Construction and application of a diagnostic marker for Parkinson's disease based on gut microbiomics | Construction and application of a diagnostic marker for Parkinson's disease based on gut microbiomics | Parkinson's disease | Gold Standard:All patients satisfied the United Kingdom Parkinson's Disease Society Brain Bank criteria;Index test:Microbial gene detection chip; | Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | NULL | Recruiting | 55 | 80 | Both | Target condition:500;Difficult condition:600 | China | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | ChiCTR2000032616 | 2020-05-30 | 2020-05-04 | Assistant diagnosis machinery system development based on speech and movement sensitive device for Parkinson's disease | Parkinson's disease, Assistant diagnosis machinery system, speech, movement sensitive device | Parkinson's disease | Gold Standard:clinical outcome meet 2015 MDS-probable PD criteria;Index test:Acoustic receptive and analysis device,Wearable movement sensor; | Shanghai Jiao Tong University School of Medicine affiliated Shanghai General Hospital | NULL | Pending | Both | Target condition:20;Difficult condition:80 | China | |||
| 7 | NCT03815916 (ClinicalTrials.gov) | December 19, 2019 | 18/1/2019 | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease | A Phase 2, Pilot Open Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Parkinson's Disease | Parkinson's Disease | Drug: Gold Nanocrystals | Clene Nanomedicine | University of Texas Southwestern Medical Center | Recruiting | 30 Years | 80 Years | All | 30 | Phase 2 | United States |
| 8 | ChiCTR1900027306 | 2019-11-15 | 2019-11-08 | Application of optical coherence tomography and detection of a-synuclein in tears in the diagnosis of Parkinson's disease | Morphological changes of retina in patients with Parkinson's disease and the role of a-synuclein in retinal damage | Parkinson's disease | Gold Standard:British brain bank Parkinson's disease diagnostic criteria;Index test:Application of optical coherence tomography to observe the retinal structure of the macular area, optic disc area and the expression level of a-synuclein in tears in the diagnosis of Parkinson's disease.; | The First Affiliated Hospital of Chengdu Medical College | NULL | Recruiting | Both | Target condition:85;Difficult condition:85 | China | |||
| 9 | ChiCTR1800015757 | 2019-04-01 | 2018-04-18 | Value of 131I-MIBG salivary gland imaging in the early diagnosis of Parkinson's disease | Value of 131I-MIBG salivary gland imaging in the early diagnosis of Parkinson's disease | Parkinson's Disease | Gold Standard:PD diagnostic criteria made by MDS in 2016;Index test:reduced uptake in salivery gland and myocardium in I-131-MIBG scintigraphic imaging; | Tongji hospital, Tongji University | NULL | Pending | Both | Target condition:30;Difficult condition:30 | China | |||
| 10 | ChiCTR-DDD-16009569 | 2017-01-01 | 2016-10-24 | Differential diagnosis of primary Parkinson's disease by 18F-FDG combined with 11C-ß-CFT PET / CT imaging | Differential diagnosis of primary Parkinson's disease by 18F-FDG combined with 11C-ß-CFT PET / CT imaging | Parkinson's Disease | Gold Standard:;Index test:; | Renji hospital, School of Medicine, Shanghai Jiao Tong University | NULL | Pending | 20 | 80 | Both | Target condition:0;Difficult condition:0 | China | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | ChiCTR-DOC-16008645 | 2016-07-01 | 2016-06-15 | The study of radionuclide imaging and biomarkers in clinical diagnosis and treatment of Parkinson's disease | The study of radionuclide imaging and biomarkers in clinical diagnosis and treatment of Parkinson's disease | Parkinson Disease | Gold Standard:;Index test:; | 101th Hospital of PLA | NULL | Pending | 18 | 80 | Both | Target condition:0;Difficult condition:0 | NULL | |
| 12 | ChiCTR-DRD-16008778 | 2016-07-01 | 2016-07-04 | The study of Parkinson's disease imaging biomarkers based on MR with high resolution and multi mode | The study of Parkinson's disease imaging biomarkers based on MR with high resolution and multi mode | Parkinson`s Disease | Gold Standard:;Index test:; | Xiangyang Hospital, Hubei University of Medicine | NULL | Recruiting | Both | Target condition:0;Difficult condition:0 | China | |||
| 13 | ChiCTR-DOD-15006097 | 2015-03-18 | 2015-03-16 | The diagnostic value of olfactory-evoked potentials in Parkinson'sdisease | The diagnostic value of olfactory-evoked potentials in Parkinson'sdisease | Parkinson's disease | Gold Standard:;Index test:; | Guangdong General Hospital, Guangdong Academy of Medical Sciences | NULL | Recruiting | 50 | 80 | Both | Target condition:0;Difficult condition:0 | China | |
| 14 | ChiCTR-DDD-17010794 | 2014-11-08 | 2017-03-05 | The study on early diagnosis of Parkinson 's disease by transcranial ultrasonography | the study on early diagnosis of Parkinson 's disease by transcranial ultrasonography | Parkinson's Disease | Gold Standard:Diagnosis of Parkinson disease needs to meet 3 or more: unilateral onset;resting tremor;progressive course; long term asymmetry, the most obvious symptoms is the onset side; a good response to levodopa (70% ~ 100%); levodopa induced chorea; a reaction of levodopa lasts 5 years or more; clinical course last;Index test:Laboratory apparatus As shown in Figure 1, The ultrasound equipment, Philips IE33-BOMJH1 color Doppler ultrasonography, Model IE-ELite, with 2-4MHz phased array probe (S5-1 probe) was used for TCS to examine SN in our study. Transcranial ultrasound study Ultrasonography through temporal window, alon; | Department of Neurology, Fujian Institute of Geriatrics, Fujian Medical University Union Hospital | NULL | Completed | 36 | 84 | Both | Target condition:135;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000034098 | 2020-07-01 | 2020-06-23 | A New Quantitative Method Used to Evaluate Cervical Spinal Cord Damage in Multiple Sclerosis: Diffusional Kurtosis Imaging Research | A New Quantitative Method Used to Evaluate Cervical Spinal Cord Damage in Multiple Sclerosis: Diffusional Kurtosis Imaging Research | Multiple Sclerosis | Gold Standard:Conventional cervical MRI;Index test:Diffusional Kurtosis Imaging; | The First Hospital of Jilin University | NULL | Pending | Both | Target condition:48;Difficult condition:0 | China | |||
| 2 | NCT03993171 (ClinicalTrials.gov) | December 19, 2019 | 31/5/2019 | 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis. | A Phase 2, Open-Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis. | Relapsing Remitting Multiple Sclerosis | Drug: gold nanocrystals | Clene Nanomedicine | University of Texas Southwestern Medical Center | Recruiting | 18 Years | 55 Years | All | 30 | Phase 2 | United States |
| 3 | NCT03536559 (ClinicalTrials.gov) | November 23, 2018 | 2/5/2018 | Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis | A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis;Optic Neuropathy;Optic; Neuritis, With Demyelination | Drug: CNM-Au8;Drug: Placebo | Clene Nanomedicine | Clene Australia Pty Ltd | Recruiting | 18 Years | 55 Years | All | 150 | Phase 2 | United States;Australia;Canada |
| 4 | ChiCTR-DND-17013749 | 2017-12-01 | 2017-12-07 | Application of 3.0 T MRI 3D sequences of CUBE-T2 FLAIR?DIR for brain lesions of childhood-onset multiple sclerosis | Application of 3.0 T MRI 3D sequences of CUBE-T2 FLAIR?DIR for brain lesions of childhood-onset multiple sclerosis | childhood-onset multiple sclerosis | Gold Standard:CUBE-T2 FLAIR scanning;Index test:DIR scanning; | Children's Hospital of Chongqing Medical University | NULL | Recruiting | Both | Target condition:80;Difficult condition:0 | China | |||
| 5 | EUCTR2010-024017-31-IT (EUCTR) | 15/03/2011 | 08/02/2011 | A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy - GOLDEN | A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy - GOLDEN | Relapsing Remitting Multiple Sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10063399 | Product Name: FINGOLIMOD Product Code: FTY720D Trade Name: EXTAVIA INN or Proposed INN: Interferon beta-1b Trade Name: AVONEX INN or Proposed INN: Interferon beta-1a Trade Name: COPAXONE INN or Proposed INN: Glatiramer acetate | NOVARTIS FARMA | NULL | Not Recruiting | Female: yes Male: yes | Italy |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000033282 | 2020-06-01 | 2020-05-26 | Construction of cohort and prognosis prediction model of multiple system atrophy | Construction of cohort and prognosis prediction model of multiple system atrophy | Multiple system atrophy | Gold Standard:Clinical outcomes.;Index test:Prognosis prediction model of multiple system atrophy; | West China Hospital of Sichuan University | NULL | Recruiting | 30 | 75 | Both | Target condition:600;Difficult condition:0 | China | |
| 2 | ChiCTR-DPC-15005941 | 2015-03-01 | 2015-01-25 | Study for the diagnosis and differential diagnosis of multiple system atrophy | Study for the diagnosis and differential diagnosis of multiple system atrophy | Multiple system atrophy | Gold Standard:electrophysiological techniques;Index test:brain MRI; | Navy general hospital | NULL | Completed | 30 | 80 | Both | Target condition:260;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000036770 | 2020-10-01 | 2020-08-25 | Establishment of prediction model of selumetinib therapy in the treatment of plexiform neurofibroma based on exosomes test from liquid biopsy | Establishment of prediction model of selumetinib therapy in the treatment of plexiform neurofibroma based on exosomes test from liquid biopsy | Plexiform Neurofibromatosis type 1 | Gold Standard:Clinical outcomes;Index test:Prediction model of selumetinib therapy in the treatment of plexiform neurofibroma based on exosomes test from liquid biopsy; | Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine | NULL | Pending | 2 | 65 | Both | Target condition:32;Difficult condition:0 | China | |
| 2 | ChiCTR-DDD-16009551 | 2016-10-28 | 2016-10-23 | Comparative study of Sanger sequencing and specific panel high-throughput sequencing for detection of NF1 pathogenic mutations in Han Chinese | Comparative study of Sanger sequencing and specific panel high-throughput sequencing for detection of NF1 pathogenic mutations in Han Chinese | neurofibromatosis;M95400/1 | Gold Standard:;Index test:; | Shanghai 9th People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine | NULL | Recruiting | 10 | 45 | Both | Target condition:0;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800018637 | 2018-09-26 | 2018-09-30 | Correlation between Human epididymis protein 4 and interstitial lung disease in patients with rheumatoid arthritis | Correlation between Human epididymis protein 4 and interstitial lung disease in patients with rheumatoid arthritis | rheumatoid arthritis | Gold Standard:Clinical outcome, meet the 2010 ACR/EULAR rheumatoid arthritis classification criteria.;Index test:Human epididymis protein 4,anti-cyclic citrullinated peptide, creatinine, rheumatoid factor; | Affiliated Hospital of North Sichuan Medical College | NULL | Recruiting | Both | Target condition:150;Difficult condition:100 | China | |||
| 2 | ChiCTR-DDT-12002658 | 2012-12-01 | 2012-11-04 | Validation of early rheumatoid arthritis classification criteria | Validation of early rheumatoid arthritis classification criteria | rheumatoid arthritis | Gold Standard:;Index test:; | Peking University People's Hospital | NULL | Completed | 16 | 100 | Both | Target condition:0;Difficult condition:0 | China | |
| 3 | ChiCTR-DDT-12002268 | 2011-06-11 | 2012-06-11 | Early diagnosis of rheumatoid arthritis | Study on the clinical application of imaging in early rheumatoid | rheumatoid arthritis | Gold Standard:;Index test:; | Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University | NULL | Completed | 18 | 65 | Both | Target condition:0;Difficult condition:0 | China | |
| 4 | EUCTR2010-019514-24-CZ (EUCTR) | 21/04/2011 | 06/12/2010 | Study to determine the effects of different doses of Methotrexate (MTX) when taken with adalimumab in subjects with Early Rheumatoid Arthritis (RA) | A Double-Blind, Randomized, Parallel-Arm, Multi-Center Study to Determine the Dose Response of Methotrexate (MTX) in Combination Therapy with Adalimumab in Subjects with Early Rheumatoid Arthritis. - CONCERTO | Rheumatoid Arthritis. MedDRA version: 14.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Humira INN or Proposed INN: ADALIMUMAB Trade Name: MTX HEXAL Tablets INN or Proposed INN: METHOTREXATE Trade Name: MTX Goldshield Tablets INN or Proposed INN: METHOTREXATE | AbbVie Deutschland GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 380 | United States;Czech Republic;Canada;Puerto Rico;Argentina;Spain;Belgium;Austria;Germany | |||
| 5 | NCT00491933 (ClinicalTrials.gov) | June 2007 | 25/6/2007 | Quantiferon-TB Gold in the Assessment of Latent TB in Patients Candidate to Treatment or Treated With TNFa Antagonists | Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing in the Assessment of Latent Mycobacterium Tuberculosis Infection in Patients Candidate to Treatment or Treated With TNFa Antagonists | Rheumatoid Arthritis;Spondylarthritis;Tuberculosis | Procedure: Quantiferon-TB Gold assay;Procedure: Tuberculin skin test | Ospedale L. Sacco – Polo Universitario | NULL | Recruiting | 18 Years | 80 Years | Both | 100 | N/A | Italy |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2007-001190-28-GB (EUCTR) | 09/05/2007 | 17/04/2007 | Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - TACIT | Randomised controlled trial of tumour-necrosis-factor inhibitors against combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis - TACIT | Rheumatoid Arthritis MedDRA version: 9.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis | Product Name: Methotrexate Product Code: Methotrexate INN or Proposed INN: METHOTREXATE Product Name: Sulfasalazine Product Code: Sulfasalazine INN or Proposed INN: SULFASALAZINE Product Name: Hydroxychloroquine Product Code: Hydroxychloroquine INN or Proposed INN: Hydroxychloroquine Product Name: Ciclosporin Product Code: Ciclosporin INN or Proposed INN: Ciclosporin Product Name: Leflunomide Product Code: Leflunomide INN or Proposed INN: Leflunomide Product Name: Sodium aurothiomalate (intramuscular gold) Product Code: Sodium aurothiomalate (intramuscular gold) INN or Proposed INN: Sodium aurothiomalate Product Name: methylprednisolone Product Code: methylprednisolone INN or Proposed INN: Methylprednisolone Product Name: Prednisolone Product Code: Predniso | King's College London | NULL | Not Recruiting | Female: yes Male: yes | 190 | Phase 4 | United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000038519 | 2020-10-01 | 2020-09-23 | A study of T lymphocyte subsets in children with systemic lupus erythematosus | A study of T lymphocyte subsets in children with systemic lupus erythematosus | systemic lupus erythematosus in children | Gold Standard:anti-nuclear antibodies;Index test:WBC, CD4+T cells, CD4+CCR7+CD95+T cells, CD4+CD45RA-CCR7+T cells, CD4+CD45RA-CCR7-Tcells; | Tianjin Children's Hospital | NULL | Pending | 8 | 17 | Both | Target condition:100;Difficult condition:50 | N/A | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000031286 | 2020-03-27 | 2020-03-26 | Establishment and validation of the risk prediction model of dermatomyositis combined with malignant tumor nomogram | Establishment and validation of the risk prediction model of dermatomyositis combined with malignant tumor nomogram | Dermatomyositic | Gold Standard:Clinical outcomes (whether combined with malignant tumor);Index test:The risk prediction model of dermatomyositis combined with malignant tumor nomogram; | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | NULL | Recruiting | 85 | 1 | Both | Target condition:240;Difficult condition:0 | China | |
| 2 | ChiCTR-DDD-16009687 | 2016-10-28 | 2016-10-28 | The precision diagnosis of dermatomyositis with malignant tumor or fatal interstitial lung disease | The precision diagnosis of dermatomyositis with malignant tumor or fatal interstitial lung disease | Dermatomyositis | Gold Standard:;Index test:; | Department of Dermatology, Rui Jin Hospital, School of Medicine, Shanghai Jiao Tong University | NULL | Recruiting | 18 | Both | Target condition:0;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000035194 | 2020-10-01 | 2020-08-02 | The value of exosome miR29 for biomarker of primary Sjogren's syndrome with interstitial lung disease | The value of exosome miR29 for biomarker of primary Sjogren's syndrome with interstitial lung disease | Sjogren's syndrome; Interstitial lung disease | Gold Standard:According to the clinical manifestations, chest imaging (cell-like change, ground glass change, solid shadow, mesh shadow), lung ventilation and diffusion function (FVC, DLCO), pathological biopsy and the elimination of ILD caused by other known reasons. If necessary, a surgical lung biopsy is feasible.;Index test:miRNA-29; | Tongji Hosipital, Tongji University School of Medicine | NULL | Recruiting | 18 | Both | Target condition:60;Difficult condition:60 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000032139 | 2020-09-01 | 2020-04-20 | Newborn screening and precision medical system construction for primary immunodeficiency disease | Newborn screening and precision medical system construction for primary immunodeficiency disease | primary immunodeficiency | Gold Standard:1. Whether there is immune deficiency; 2. Primary or secondary, persistent or temporary; 3. The part and degree of the defect of immune system; 4. Molecular diagnosis: sequence the first / second generation genes to detect whether there is pathogenic gene mutation; detection of relative protein molecular.;Index test:PID newborn screening technology system based on TRECs/KRECs combined with quantitative PCR detection; | Children's Hospital of Chongqing Medical University | NULL | Recruiting | 0 | 1 | Both | Target condition:50000;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000030380 | 2020-02-15 | 2020-02-29 | The diagnostic accuracy of CT-based ''Banner cloud sign'' for dural ossification in patients with thoracic ossification of the ligamentum flavum: a prospective, blinded, diagnostic accuracy study protocol | The diagnostic accuracy of CT-based ''Banner cloud sign'' for dural ossification in patients with thoracic ossification of the ligamentum flavum: a prospective, blinded, diagnostic accuracy study protocol | ossification of ligamentum flavum combined with dural ossification | Gold Standard:Operation notes.;Index test:CT images of thoracic spine: Banner clouds sign, Tram track sign and Comma sign.; | Peking University Third Hospital | NULL | Recruiting | 0 | 99 | Both | Target condition:132;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000034464 | 2020-09-01 | 2020-07-05 | First Morning Voided Urinary Gonadotropin Measurements for the Early Screening, Diagnosis and Follow-up of CPP Patients | First Morning Voided Urinary Gonadotropin Measurements for the Early Screening, Diagnosis and Follow-up of CPP Patients | Central precocious puberty | Gold Standard:Clinical outcome by CPP diagnostic standards;Index test:morning urine GN; | Department of Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology | NULL | Pending | 6 | 12 | Both | Target condition:400;Difficult condition:6000 | China | |
| 2 | ChiCTR2000038202 | 2020-09-01 | 2020-09-13 | AMH combined INHB for the diagnosis of female central precocious puberty | AMH combined INHB for the diagnosis of female central precocious puberty | Central precocious puberty | Gold Standard:GnRHa provoctive test;Index test:Anti Mullerian hormone, Inhibin B; | Capital Institute of Pediatrics | NULL | Recruiting | 5 | 8 | Female | Target condition:150;Difficult condition:150 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000036043 | 2020-10-01 | 2020-08-21 | A prospective, single-centre, diagnostic accuracy study of XpertMTB/RIF Ultra to differentiate atypical tuberculosis from sarcoidosis | A prospective, single-centre, diagnostic accuracy study of XpertMTB/RIF Ultra to differentiate atypical tuberculosis from sarcoidosis | sarcoidosis, tuberculosis | Gold Standard:Biopsy pathological specimen, and sputum AFB smear;Index test:XpertMTB/RIF Ultra; | Shanghai Pulmonary Hospital Tongji University, School of Medicine | NULL | Pending | 18 | Both | Target condition:72;Difficult condition:72 | China | ||
| 2 | ChiCTR-DCD-15007110 | 2015-09-01 | 2015-09-20 | The clinical application of new methods for differential diagnosis of sarcoidosis andsputum negative tuberculosis | The clinical application of new methods for differential diagnosis of sarcoidosis andsputum negative tuberculosis | sarcoidosis andsputum negative tuberculosis | Gold Standard:;Index test:; | Department of Respiratory Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine | NULL | Recruiting | 18 | Both | Target condition:0;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000036852 | 2020-10-01 | 2020-08-25 | Establishment of an artificial intelligence screening and evaluation system based on multimodal imaging of pulmonary arterial hypertension: Study on clinical diagnosis model | Establishment of an artificial intelligence screening and evaluation system based on multimodal imaging of pulmonary arterial hypertension: Study on clinical diagnosis model | pulmonary arterial hypertension | Gold Standard:Right heart catheterization;Index test:multimodal imaging artificial intelligence screening and evaluation system; | Shanghai Pulmonary Hospital | NULL | Pending | Both | Target condition:1000;Difficult condition:1000 | NULL | |||
| 2 | ChiCTR2000032622 | 2020-05-01 | 2020-05-04 | Research for right cardiac function evaluation and warning model of neonatal pulmonary arterial hypertension | Research for right cardiac function evaluation and warning model of neonatal pulmonary arterial hypertension | pulmonary arterial hypertension | Gold Standard:Clinical outcome;Index test:echocardiographic; | Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital | NULL | Pending | Male | Target condition:100;Difficult condition:0 | China | |||
| 3 | ChiCTR1900028152 | 2020-01-01 | 2019-12-13 | Serum interleukins-6: a predictive biomarker for connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) | Serum interleukins-6: a predictive biomarker for connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) | pulmonary arterial hypertension | Gold Standard:Clinical outcome;Index test:serum IL-6; | Zhongda Hospital Affiliated to Southeast University | NULL | Pending | 18 | 80 | Both | Target condition:200;Difficult condition:0 | N/A | China |
| 4 | ChiCTR-DDD-16009406 | 2016-11-01 | 2016-10-14 | System Construction of Precious Diagnosis and Evaluation for Pulmonary Arterial Hpyertension | System Construction of Precious Diagnosis and Evaluation for Pulmonary Arterial Hpyertension | Pulmonary arterial hypertension | Gold Standard:;Index test:; | Shanghai Pulmonary Hospital | NULL | Pending | Both | Target condition:0;Difficult condition:0 | China | |||
| 5 | NCT01457170 (ClinicalTrials.gov) | January 2012 | 20/10/2011 | Effects of Apelin on the Lung Circulation in Pulmonary Hypertension | Investigating the Acute Pulmonary Vascular Haemodynamic Effects of Apelin in Pulmonary Hypertension | Pulmonary Arterial Hypertension;Heart Failure | Drug: Apelin;Drug: Saline (Placebo) | Golden Jubilee National Hospital | NHS Lothian;Imperial College Healthcare NHS Trust | Recruiting | 18 Years | N/A | Both | 63 | N/A | United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800017925 | 2018-08-31 | 2018-08-22 | D-printed bidirectional angiography versus traditional angiography for the diagnosis and effect of Budd–Chiari Syndrome With Inferior Vena Cava Obstruction:-----A Prospective Single blind Randomized Trial | D-printed bidirectional angiography versus traditional angiography for the diagnosis and effect of Budd–Chiari Syndrome With Inferior Vena Cava Obstruction:-----A Prospective Single blind Randomized Trial | Budd-Chiari syndrome | Gold Standard:traditional angiography;Index test:3D-printed bidirectional angiography; | Affiliated Hospital of Xuzhou Medical University | NULL | Pending | 19 | 68 | Both | Target condition:60;Difficult condition:0 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000032053 | 2020-05-01 | 2020-04-19 | Application value of ultrasonography combined with transient elastography for staging of hepatic fibrosis in patients with primary biliary cholangitis (PBC) | Application value of ultrasonography combined with transient elastography for staging of hepatic fibrosis in patients with primary biliary cholangitis (PBC) | primary biliary cholangitis | Gold Standard:Any two of the following items met: 1. increased biochemical indicators of cholestasis such as alkaline phosphatase; 2. positive serum AMA or AMA-M2; 3. hepatic histopathology.;Index test:high-frequency and low-frequency ultrasound?transient elastography (TE); | You'an Hospital, Capital Medical University | NULL | Pending | 18 | 70 | Both | Target condition:100;Difficult condition:270 | N/A | China |
| 2 | ChiCTR1900024836 | 2019-07-30 | 2019-07-30 | Exploration of non-invasive diagnostic model of liver fibrosis based on artificial intelligence in primary biliary cholangitis Clinical research protocol | Exploration of non-invasive diagnostic model of liver fibrosis based on artificial intelligence in primary biliary cholangitis Clinical research protocol | Primary biliary cholangitis | Gold Standard:Liver biopsy pathology.;Index test:Non-invasive diagnostic model for liver fibrosis: including AST/PLT value index (APRI model), Forns model, S index, and based on this, a new non-invasive liver fibrosis diagnosis model is generated.; | Beijing You'an Hospital, Capital Medical University | NULL | Recruiting | 18 | 80 | Both | Target condition:180;Difficult condition:180 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000031051 | 2020-05-01 | 2020-03-21 | Study on the early diagnosis and prediction model of autoimmune hepatitis based on noninvasive clinical data | Study on the early diagnosis and prediction model of autoimmune hepatitis based on noninvasive clinical data | Autoimmune hepatitis | Gold Standard:liver biopsy;Index test:the early diagnosis and prediction model of autoimmune hepatitis based on noninvasive clinical data; | The Sixth People's Hospital Affiliated To Shanghai Jiaotong University | NULL | Pending | Male | Target condition:238;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000037094 | 2020-09-01 | 2020-08-26 | Discovery and detection of a novel antigen for Crohn’s disease (CD) | Discovery and detection of a novel antigen for Crohn’s disease (CD) | Inflammatory Bowel Disease | Gold Standard:Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing);Index test:anti-CABP, pANCA, ASCA; | The First Affiliated Hospital of Anhui Medical University | NULL | Completed | 18 | 80 | Both | Target condition:100;Difficult condition:100 | China | |
| 2 | ChiCTR2000029543 | 2020-02-08 | 2020-02-03 | A Model with serum biomarkers to Predict Infliximab Response in Patients with Crohn's Disease | A Model with serum biomarkers to Predict Infliximab Response in Patients with Crohn's Disease | Crohn's Disease | Gold Standard:Histology pathological examination; SES-CD endoscopy score;Index test:ELISA test for multiple serum cytokines; | The First Hospital Affiliated to Sun Yat sen University | NULL | Recruiting | Both | Target condition:350;Difficult condition:0 | China | |||
| 3 | ChiCTR1900022728 | 2019-05-01 | 2019-04-23 | Cohort study combined with omics screening for the early diagnostic markers in Crohn's disease | Cohort study combined with omics screening for the early diagnostic markers in Crohn's disease | Crohn's disease | Gold Standard:Clinical outcome;Index test:Comprehensive serological markers, metabolomics, intestinal microbes, pathological features, imaging features of clinical subclinical CD, combined with clinical and endoscopic features, to explore early diagnosis of CD; | The 7th Medical Center of the PLA General Hospital (Army general hospital) | NULL | Pending | Both | Target condition:310;Difficult condition:160 | China | |||
| 4 | ChiCTR-DDT-14004999 | 2013-07-01 | 2014-07-17 | Endoscopic Ultrasonography (EUS) Helps Differentiate Crohn's Disease from Intestinal Tuberculosis | Endoscopic Ultrasonography (EUS) Helps Differentiate Crohn's Disease from Intestinal Tuberculosis | Crohn's disease and intestinal tuberculosis | Gold Standard:;Index test:; | West China Hospital, Sichuan University | NULL | Completed | 16 | 41 | Both | Target condition:0;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800019676 | 2018-12-01 | 2018-11-22 | Diagnostic Value of probe-based Confocal Laser Endomicroscopy Score for assessment of numosal healing of ulcerative colitis | Diagnostic Value of probe-based Confocal Laser Endomicroscopy Score for assessment of numosal healing of ulcerative colitis: a single center, prospective cohort study | ulcerative colitis | Gold Standard:Histopathological examination;Index test:1, Gland density (grade) 2. Gland morphology (grade) 3. Vascular changes (grade); | Peking University First Hospital | NULL | Pending | 18 | 80 | Both | Target condition:40;Difficult condition:0 | China | |
| 2 | ChiCTR1900023689 | 2012-03-01 | 2019-06-07 | Comparison of white light endoscopy vs chromoendoscopy in the detection rate of dysplasia and colorectal cancer in ulcerative colitis: A Multicenter Long-term Follow-up Randomized Controlled Trial in China | Comparison of white light endoscopy vs chromoendoscopy in the detection rate of dysplasia and colorectal cancer in ulcerative colitis: A Multicenter Long-term Follow-up Randomized Controlled Trial in China | Ulcerative colitis | Gold Standard:Pathological examination;Index test:1. targeted biopsies were taken from all visible lesions when using white light endoscopy 2. using white light endoscopy, sequential 4-quadrantic random biopsies were taken at every 10-cm intervals colon from disease segments defined by the endoscopist in addition to targeted biopsies from all visible lesions; 3. tar; | Xijing Hospital of Digestive Diseases, Fourth Military Medical University | NULL | Completed | 18 | 70 | Both | Target condition:141;Difficult condition:0 | N/A | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-DOD-16009003 | 2016-08-04 | 2016-08-10 | Perspective Study On Eosinophilic Gastroenteritis | Perspective Study On Eosinophilic Gastroenteritis | Eosinophilic Gastroenteritis | Gold Standard:;Index test:; | Endoscopy Center, Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-sen University. | NULL | Recruiting | Both | Target condition:0;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800018340 | 2018-09-12 | 2018-09-12 | Clinical study for cardiac MRI in evaluating early myocardial lesions in patients with muscular dystrophy | Clinical study for cardiac MRI in evaluating early myocardial lesions in patients with muscular dystrophy | Muscular dystrophy | Gold Standard:Genomic sequencing, muscle biopsy;Index test:Myocardial strain, T1/T2mapping value, late delayed enhancement (LGE), myocardial first pass perfusion; | Department of Radiology, West China Second Hospital, Sichuan University | NULL | Recruiting | 4 | 18 | Male | Target condition:200;Difficult condition:30 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-DDD-17010586 | 2016-01-01 | 2017-02-08 | Prenatal diagnosis of tuberous sclerosis by fetal echocardiography combined with high throughput gene sequencing | Prenatal diagnosis of TSC using high-throughput gene sequencing combined with fetal echocardiography | Tuberous sclerosis complex | Gold Standard:A Clinical diagnostic criteria of tuberous sclerosis (TSC) for the postnatal population 1. Definite diagnosis: 2 major features or 1 major feature and 2 minor teatures 2. Possible diagnosis: 1 major feature or 2 minor features [major features: (1) Facial angiofibro or forehead plaque, (2) 'Nontraumatic' periungual&#;Index test:1. Prenatal diagnosis of TSC high-risk fetus by the traditional method (amniocentesis) using the gold standard; 2. Prenatal diagnosis of TSC high-risk fetus by maternal peripheral blood gene detection.; | An Zhen Hospital affiliated to Capital Medical University, Beijing;Beijing Key Laboratory of Fetal Heart Diseases and Maternal-Fetal Medicine | NULL | Recruiting | Female | Target condition:30;Difficult condition:5 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800017560 | 2018-08-31 | 2018-08-04 | Association of serum D-dimer and PDF with the BP severity | Association of serum D-dimer and PDF with the BP severity | Bullous pemphigoid | Gold Standard:Clinical outcome;Index test:D-dimer, FDP, anti-BP180 IgG; | the Second Affiliated Hospital, Xi'an Jiaotong University | NULL | Pending | 18 | 90 | Both | Target condition:160;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900023410 | 2019-06-01 | 2019-05-26 | The application of quantitative susceptibility mapping and blood and urine cell culture in Wilson's disease | The application of quantitative susceptibility mapping and blood and urine cell culture in Wilson's disease | Wilson’s disease | Gold Standard:The main clinical diagnostic criteria: 1) liver disease history, liver disease symptoms or extravertebral system symptoms; 2) serum ceruloplasmin was significantly decreased and/or liver copper increased; 3) corneal Kayser-Fleischer ring; 4) positive family history.;Index test:Quantitative susceptibility mapping; | Shanghai Tongren Hospital | NULL | Recruiting | Both | Target condition:40;Difficult condition:20 | China | |||
| 2 | ChiCTR-DDD-17010552 | 2017-01-25 | 2017-02-04 | Genetic diagnosis of Wilson's disease | Genetic diagnosis of Wilson's disease | Wilson Disease | Gold Standard:Clinical symptoms; Family history of genetic; Plasma ceruloplasmin levels;Urine copper levels of 24 hours; The nervous system of assessment and head imaging examination;Index test:Determination of gene sequence of the gene of ATP7B; | Anhui Provincial Hospital | NULL | Recruiting | Both | Target condition:20;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000036550 | 2020-09-01 | 2020-08-24 | Enzyme-linked immunosorbent determination of urine IV collagen alpha chain early warning value for Alport syndrome | Enzyme-linked immunosorbent determination of urine IV collagen alpha chain early warning value for Alport syndrome | Alport syndrome | Gold Standard:Renal biopsy, skin biopsy and genetic test.;Index test:urine IV collagen a chain test; | Children's Hospital of Shanghai | NULL | Recruiting | 0 | 18 | Both | Target condition:60;Difficult condition:70 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000037467 | 2020-12-31 | 2020-08-28 | Effect of Tripterygium wilfordii polyglycoside tablets on the inhibition of TM on complement pathway and related inflammatory markers in membranous nephropathy | The complement pathway and related inflammatory factor markers in the treatment of idiopathic membranous nephropathy | idiopathic membranous nephropathy | Gold Standard:Cell hemolysis test;Index test:Immunochemiluminescence (ECL) and flow cytometry (FCM) were used to determine the activity of each complement pathway and the target of complement; Complement hemolysis test is usually used to determine the activity of total complement and single complement component, but it is difficult to be applied to clinical ; | Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine | NULL | Pending | 18 | 80 | Both | Target condition:40;Difficult condition:40 | China | |
| 2 | NCT04387448 (ClinicalTrials.gov) | July 28, 2020 | 11/5/2020 | A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease | A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease | Kidney Diseases;Diabetic Nephropathies;Glomerulosclerosis, Focal Segmental;Nephrosis, Lipoid;Urologic Diseases;Diabetes Complications;Diabetes Mellitus;Endocrine System Diseases;Glomerulonephritis;Nephritis;Nephrosis | Drug: GFB-887;Drug: Placebo | Goldfinch Bio, Inc. | NULL | Recruiting | 18 Years | 75 Years | All | 125 | Phase 2 | United States |
| 3 | ChiCTR1900027128 | 2019-10-30 | 2019-11-01 | Validation of Anti-Phospholipase A2 Receptor Antibody ELISA in a Chinese Cohort With Idiopathic Membranous Nephropathy: a Multicenter Observational Study | The Cut-off Value of Anti-Phospholipase A2 Receptor Antibody ELISA in Chinese Patients | Membranous Nephrology | Gold Standard:Pathological diagnosis according to kidney biopsy(Chapter 7, 7.1 Evaluation of MN, KDIGO 2012);Index test:Serum PLA2R Antibody by ELISA; | Department of Nephrology, The First Affiliated Hospital of Shandong First Medical University | NULL | Recruiting | Both | Target condition:288;Difficult condition:290 | N/A | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1800017046 | 2018-07-15 | 2018-07-10 | The research of Gd - IgA1 with purpura nephritis | The research of Gd - IgA1 with purpura nephritis | Henoch-Schnlein purpura nephritis;D69.005+ | Gold Standard:Allergic purpura diagnostic criteria: 1) the tangibility purpura; 2) the onset age < 20 years old; 3) with acute abdominal pain; 4) biopsy showed small veins and arteries around a neutrophil infiltration. In the above four standard, conform to article 2 or above can be diagnosed as allergic purpura. Purpur;Index test:Gd-IgA1, IgA, IgG, C3; | College of Pediatrics, University of South China/Children's Hospital of Hu'nan Province | NULL | Recruiting | 1 | 14 | Both | Target condition:250;Difficult condition:24 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900027420 | 2018-01-01 | 2019-11-12 | genetic screening for hereditary hemorrhagic telangiectasia | Investigation and applyling on the genetic screening kit for hereditary hemorrhagic telangiectasia | hereditary hemorrhagic telangiectasia | Gold Standard:Clinical outcomes;Index test:To identified the pathogenic variant through genetic testing for the coding region of ENG, ACVRL1, SMAD4 and BMP9.; | Beijing Institute of Otolaryngology | NULL | Recruiting | Both | Target condition:54;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-DDT-11001215 | 2010-07-01 | 2011-03-05 | Double position CT investigation of OSAHS | Double position CT investigation of OSAHS | Obstructive sleep apnea hypoventilation syndrome | Gold Standard:;Index test:; | First Hospital of Peking university | NULL | Completed | Both | Target condition:0;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR-DDD-17014196 | 2018-01-01 | 2017-12-28 | HLA-B27 tested by different methods and comparison | HLA-B27 tested by different methods and comparison | Ankylosing spondylitis | Gold Standard:Detect HLA-B27 by cytometry;Index test:SSP and SSO; | Dalian Blood Center | NULL | Recruiting | 5 | 90 | Both | Target condition:200;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000035860 | 2020-10-01 | 2020-08-18 | Artificial intelligence for pathological grading system of ganglion cells for intraoperative rapid biopsy in Hirschsprung disease | Artificial intelligence for pathological grading system of ganglion cells for intraoperative rapid biopsy in Hirschsprung disease | Hirschsprung disease | Gold Standard:The speciemens and sections will be reveiwed by three senior pediatric gastroenterology pathologists under the novel pathological grading system of ganglion cells in Hirschsprung disease, and the results is regarded as the gold standard.;Index test:Artificial intelligence assisted whole-section patholgic diagnosis system; | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | NULL | Pending | 0 | 16 | Both | Target condition:138;Difficult condition:138 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00257946 (ClinicalTrials.gov) | December 2005 | 22/11/2005 | Type of Material in Repair of Congenital Diaphragmatic Hernia | Prospective Randomized Trial Comparing Type of Material in Repair of Congenital Diaphragmatic Hernia | Congenital Diaphragmatic Hernia | Procedure: Repair of CDH w/SIS Gold;Procedure: Repair of CDH w/Alloderm | Children's Mercy Hospital Kansas City | NULL | Terminated | N/A | 2 Months | Both | 50 | Phase 3 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000032983 | 2020-08-01 | 2020-05-17 | Development of Biomarkers for Biliary Atresia and Establishment of Artificial Intelligence Diagnostic Model | Development of Biomarkers for Biliary Atresia and Establishment of Artificial Intelligence Diagnostic Model | Biliary atresia | Gold Standard:Cholangiography combined with liver biopsy;Index test:MMP7;bile acid profile; | Children's Hospital of Fudan University | NULL | Recruiting | Both | Target condition:600;Difficult condition:600 | China | |||
| 2 | ChiCTR2000034127 | 2020-07-20 | 2020-06-25 | Application of MMP-7 in early diagnosis of neonatal biliary atresia | Application of MMP-7 in early diagnosis of neonatal biliary atresia | Biliary atresia disease | Gold Standard:Laparoscopic cholangiography;Index test:Serum MMP-7; | Department of Pediatric Surgery, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology | NULL | Pending | 0.1 | Both | Target condition:300;Difficult condition:0 | China | ||
| 3 | ChiCTR1800019866 | 2019-01-01 | 2018-12-02 | Development and validation of novel diagnostic model for biliary atresia | Development and validation of novel diagnostic model for biliary atresia: a multicenter diagnostic test | biliary atresia | Gold Standard:cholangiography combined with liver biopsy;Index test:Nomogram; | Children's Hospital of Fudan University | NULL | Pending | Both | Target condition:1000;Difficult condition:200 | China | |||
| 4 | ChiCTR1800017428 | 2018-08-15 | 2018-07-30 | Machine learning based on the gallbladder morphology for screening biliary atresia among infants with conjugated hyperbilirubinemia | Machine learning based on the gallbladder morphology for screening biliary atresia among infants with conjugated hyperbilirubinemia | Biliary atresia | Gold Standard:Surgical exploration, puncture biopsy, intraoperative cholangiography or percutaneous cholecystography;Index test:machine learning based on the gallbladder morphology; | Department of Medical Ultrasonics, the First Affiliated Hospital of Sun Yat-sen University | NULL | Pending | Both | Target condition:500;Difficult condition:100 | China | |||
| 5 | ChiCTR-DPD-15005847 | 2014-11-19 | 2015-01-19 | Evidence-based guideline of diagnosis and treatment of biliary atresia | Evidence-based guideline of diagnosis and treatment of biliary atresia | biliary atresia | Gold Standard:;Index test:; | Children's Hospital of Fudan University | NULL | Pending | 0 | 18 | Both | Target condition:0;Difficult condition:0 | I (Phase 1 study) | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000037002 | 2020-10-01 | 2020-08-26 | Differential diagnosis of pancreatic cancer and chronic pancreatitis with serum miR-25 | A prospective study of serum miR-25 detection in differential diagnosis of pancreatic cancer and chronic pancreatitis | pancreatic cancer | Gold Standard:Pancreatic cancer: pancreatic ductal adenocarcinoma originating from pancreatic ductal epithelium was confirmed by pathological examination (operative biopsy, puncture biopsy, cytological examination). Chronic pancreatitis: Clinically diagnosed as chronic pancreatitis, and no evidence to support the diagnosis of pancreatic cancer.;Index test:Serum miR-25; | The First Affiliated Hospital of the Naval Medical University of the Chinese People's Liberation Army | NULL | Pending | 18 | 75 | Both | Target condition:150;Difficult condition:150 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02717650 (ClinicalTrials.gov) | August 25, 2016 | 10/3/2016 | The Alfred Step Test Exercise Protocol (A-STEP), for Adults With Cystic Fibrosis. | Development; Feasibility/Safety and Validation of the Alfred Step Test Exercise Protocol (A-STEP) Developed for Adults With Cystic Fibrosis: | Cystic Fibrosis;Fibrosis;Lung Diseases;Respiratory Diseases;Genetic Diseases;Pancreatic Diseases | Other: A-STEP;Other: A-STEP (New Protocol);Other: Comparator: CPET cycle ergometer (Gold Standard) | The Alfred | Monash University | Suspended | 18 Years | N/A | All | 30 | N/A | Australia |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000035477 | 2020-08-11 | 2020-08-12 | Clinical study on the diagnosis of Smith Lemli Opitz syndrome by GC-MS | Clinical study on the diagnosis of Smith Lemli Opitz syndrome by GC-MS | Smith-Lemli-Opitz syndrome | Gold Standard:Quantitative detection of 7-DHC;Index test:Detection of chol and 7-DHC in clinical samples by GC-MS; | Obstetrics and Gynecology Hospital Affiliated to Fudan University | NULL | Pending | 0 | 1 | Both | Target condition:110;Difficult condition:0 | China |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2000038114 | 2020-09-15 | 2020-09-11 | Molecular Diagnostic Study and Clinical Management of citrin deficiency | Molecular Diagnostic Study and Clinical Management of citrin deficiency | Citrin deficiency | Gold Standard:Sanger sequncing;Index test:Next-Generation Sequncing; | Beijing Friendship Hospital Affiliated to Capital Medical University | NULL | Recruiting | Both | Target condition:60;Difficult condition:0 | N/A | China |